Healthcare startup Synthio Labs has raised $5 million in a seed funding round led by Elevation Capital, while 1984 Ventures, Peak XV Partners, Y Combinator, and several healthcare and AI-focused angel investors also participated.
The company operates as a healthcare-centric voice AI platform that enables pharmaceutical companies to automate engagement with both doctors and patients.
Synthio Labs explains that global pharma companies spend over $30 billion annually on doctor and patient engagement; however, outreach still remains manual, fragmented, and difficult to scale. Moreover, doctors often experience significant information overload, while many patients—especially those managing chronic illnesses—lack continuous support, which contributes to treatment drop-off rates reaching nearly 50%. The startup aims to solve these challenges through compliant, real-time voice AI that delivers accurate medical information whenever needed.
CEO and co-founder Supreet Deshpande emphasized that the future of healthcare will depend not only on breakthrough therapies but also on “how we reach and support every clinician and patient who relies on them.” Additionally, CTO and co-founder Rajashekar Vasantha stated that Synthio is building AI infrastructure to enable this support “intelligently, compliantly, and at scale.”
Synthio’s AI operating system integrates three core products: Jarvis, a clinical-grade voice AI copilot designed for pharma field teams; Ather, a multimodal AI engine that powers omnichannel engagement; and Simulation Studio, a digital-twin platform that models clinician and patient behavior for research and strategy. Together, these tools automate compliant conversations, generate structured insights, and standardize communication across large life sciences organizations.
Several top 10 global pharma companies and major D2C healthcare brands already use these solutions. In one deployment, Synthio’s voice AI delivered highly personalized support to more than 5,000 eczema patients in just 48 hours, demonstrating its ability to scale engagement rapidly.
Founded by Supreet Deshpande, Sahitya Sridhar, and Rajashekar Vasantha, Synthio Labs has strong India roots, as the founding team gained academic and professional experience in Karnataka and Chennai. Their backgrounds include roles at McKinsey, ZS Associates, Amazon, and Audible, where they contributed to large-scale pharma commercial work and key advancements in LLM and voice-tech development.
Operating teams in both India and the United States, the company plans to use the newly raised capital to expand engineering and product capabilities, scale deployments across the U.S. and Europe, and strengthen partnerships with global life sciences companies. Synthio aims to establish AI-driven engagement as the new worldwide standard for clinician and patient support.
Krishna Mehra, AI Partner at Elevation Capital, stated that Synthio is building the “next major customer engagement infrastructure for life sciences,” noting that the trillion-dollar pharma commercial system is “ripe for reinvention.”
Although voice automation in healthcare continues to grow, Synthio Labs works in a specialized niche: clinical-grade voice AI tailored specifically for life sciences engagement. While certain startups build voice assistants for healthcare, most solutions focus on hospital operations, appointment workflows, or patient triage rather than pharma-doctor communication.
Competitors like Tovie AI, Gnani.ai, Botphonic, and Convozen AI primarily support hospitals and clinics by automating appointment scheduling, symptom assessment, and administrative tasks. Others, such as ElevenLabs and DeepforgeAI, develop voice agents for patient access and call-center automation.
However, very few companies address the commercial side of life sciences as directly as Synthio Labs. By prioritizing compliant medical conversations, field-team copilots, and clinician-patient digital twins, the company presents itself not merely as another conversational AI product but as an AI infrastructure layer for pharma engagement—one that aims to unify how drugmakers communicate with doctors and patients across the globe.
